Boston Scientific stock
BSXNYSEBoston Scientific Corporation, HealthcareISIN US1011371077
63Score 63 out of 100, Neutral
Price and trend
53 / 100
Price history
−56% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 17% below it.
Since October 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 57% below its 52-week high. Largest decline in 20 years: 73% (January 2007 to July 2012).
Chart figures for advanced users
- SMA 50$44.15
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$54.63
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$41.58
- The lowest closing price of the last twelve months.
- Resistance$104.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Boston Scientific Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $65.41B, is number 4 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $20.07B (up 19.9% year on year) and earnings of $2.89B (up 55.7%).
- For fiscal 2026, analysts expect on average revenue of $20.98B (up 4.5%) and adjusted earnings per share of $3.16 (up 3.7%).
Show more
- MEQIRI Score 63 out of 100 (Neutral): rank 233 of 714 in Healthcare, median 53.
- The P/E is 18.7 (Medical (Devices) median 29, own median of recent years 57.4).
- Our model puts fair value at $57.61, with the price 22% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 18.7, Medical (Devices) median 29, own median 57.4.Valuation 64
- High marginNet margin 16.6% over the last 12 months, Medical (Devices) median 3.2%.Profitability 73
Weaknesses
- Share price fell sharplyDown 55% over the last 12 months.Momentum 31
Its standout strengths are fundamentals and growth, while capital allocation and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price far below its 52-week high
What lowers it
- price not overheated over the past year
- solid fundamentals
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $44.31 and expensive above $82.30 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $45.22 (cash-flow model) and $69.99 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.9%. At 9.9% the fair value would be $53.79, at 7.9% it would be $63.32.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.9% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating 20%, net 14%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 28 Oct 2026EPS reported $0.73 (expected $0.73)in line with expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 7.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $3.16−2.6%
- Revenue
- $20.98B−1.0%
- Earnings per share
- $3.13−7.6%
- Revenue
- $20.88B−6.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −5.3%Boston Scientific lowered its Q4 outlook to organic revenue decline of 1% to 3% and expects 2027 to be a cyclical trough with risk to revenue and earnings growth, hurt by the cyber incident, PFA market share losses and China pricing pressure.
“Q3 total company organic sales grew 1.5% our original guide of 3% to 5% Q3 adjusted EPS of $0.73 $0.73 declined 3% versus our guidance range of $8.00 to $8.02 Our Q3 results were impacted by our previously reported cyber security incident which we estimate reduced our sales growth by approximately 300 basis points …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
4 insiders bought on the open market between 31 Jul 2026 and 25 Aug 2026, $9.49M in total.
- Morano Susan EPurchase
25 Aug 2026, Board
- Shares
- 2,040
- Price
- $49.22
- Value
- $100,408
- Habiger David CPurchase
5 Aug 2026, Board
- Shares
- 2,100
- Price
- $47.59
- Value
- $99,937
- Habiger David CPurchase
4 Aug 2026, Board
- Shares
- 140
- Price
- $48.59
- Value
- $6,802
Show 7 more
- Habiger David CPurchase
3 Aug 2026, Board
- Shares
- 1,042
- Price
- $48.07
- Value
- $50,084
- Mahoney Michael FPurchase
3 Aug 2026, Chairman, President & CEO
- Shares
- 186,240
- Price
- $48.33
- Value
- $9M
- Ludwig Edward JPurchase
31 Jul 2026, Board
- Shares
- 5,000
- Price
- $45.48
- Value
- $227,400
- Pegus CherylPurchase
20 May 2026, Board
- Shares
- 1,770
- Price
- $56.49
- Value
- $99,987
- Ludwig Edward JPurchase
20 May 2026, Board
- Shares
- 3,580
- Price
- $56.68
- Value
- $202,914
- Habiger David CPurchase
20 May 2026, Board
- Shares
- 2,250
- Price
- $55.92
- Value
- $125,819
- Habiger David CPurchase
19 May 2026, Board
- Shares
- 2,200
- Price
- $56.95
- Value
- $125,279
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Boston Scientific
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 63
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Abbott LaboratoriesABT $189.28B63
- Medtronic PlcMDT $129.98B70
- StrykerSYK $121.36B70
- Edwards LifesciencesEW $60.84B76
- Siemens HealthineersSHL.DE $54.2B65
- GE HealthCare TechnologiesGEHC $37.35B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
ETFs that hold Boston Scientific
Held by 105 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.72% | 0.49% | €318.39M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.07% | 0.40% | €1.49B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.99% | 0.12% | €1.34B |
Show 5 more
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.97% | 0.15% | €3.27B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.97% | 0.15% | €592.11M |
| UBS Global Gender Equality UCITS ETF hEUR accGGUE | 0.96% | 0.23% | €188.95M |
| iShares Inclusion and Diversity UCITS ETFOPEN | 0.95% | 0.25% | €76.52M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 0.72% | 0.25% | €4.18B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2022)
- Valuation signal Fairly valued since 10 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.